This application relates to compositions and methods for the treatment of glaucoma and/or ocular hypertension in mam mals utilizing prostaglandin E receptor agonists.
This application is a 371 of PCT/US99/30746 filed on Dec. 22, 1999, which claims benefit of provisional applica tion Ser. Nos. 60/113,695 and 60/113,697 both filed Dec. 24, 1998 .
FIELD OF THE INVENTION
The present invention relates to the use of certain analogs of E Series prostaglandins to treat glaucoma and ocular hypertension.
Glaucoma is a progressive disease which leads to optic nerve damage and, ultimately, total loSS of Vision. The causes of this disease have been the Subject of extensive studies for many years, but are still not fully understood. The principal Symptom of and/or risk factor for the disease is elevated intraocular pressure or ocular hypertension due to exceSS aqueous humor in the anterior chamber of the eye.
The causes of aqueous humor accumulation in the anterior chamber are not fully understood. It is known that elevated intraocular pressure ("IOP") can be at least partially con trolled by administering drugs which either reduce the production of aqueous humor within the eye, Such as beta blockers and carbonic anhydrase inhibitors, or increase the outflow of aqueous humor from the eye, Such as miotics and Sympathomimetics.
Most types of drugs conventionally used to treat glau coma have potentially serious side effects. Miotics Such as pilocarpine can cause blurring of vision and other visual side effects, which may lead either to decreased patient compli ance or to termination of therapy. Systemically administered carbonic anhydrase inhibitors can also cause Serious side effects Such as nausea, dyspepsia, fatigue, and metabolic acidosis, which side effects can affect patient compliance and/or necessitate the termination of treatment. Another type of drug, beta-blockers have increasingly become associated with serious pulmonary side effects attributable to their effects on beta-2 receptors in pulmonary tissue. Sympathomimetics, on the other hand, may cause tachycardia, arrhythmia and hypertension. Recently, certain prostaglandins and prostaglandin derivatives have been described in the art as being useful in reducing intraocular preSSure. Typically, however, proStaglandin therapy for the treatment of elevated intraocular pressure is attended by undesirable Side-effects, Such as irritation and hyperemia of varying Severity and duration. There is therefore a continu ing need for therapies which control elevated intraocular preSSure associated with glaucoma without the degree of undesirable Side-effects attendant to most conventional therapies.
Prostaglandins are metabolite derivatives of arachidonic acid. Arachidonic acid in the body is converted to prostag landin G, which is Subsequently converted to prostaglandin H. Other naturally occurring prostaglandins are derivatives of prostaglandin H. A number of different types of pros taglandins are known in the art including A, B, C, D, E, F, G, I and J-Series prostaglandins (EPO 561 073 A1). Of interest in the present invention are compounds which are believed to exhibit IOP lowering mechanisms similar to those exhibited by PGE (an E-series prostaglandin): The relationship between EP receptor activation and IOP lowering effects is also not well understood. There are currently four recognized subtypes of the EP receptor (EP, EP, EPs, and EP, J. Lipid Mediators Cell Signaling, volume 14, pages 83-87 (1996) An agent which exhibits comparable or improved efficacy, but with reduced side effects when compared to other agents, is said to have an improved therapeutic profile. It is an object of this invention to provide a class of IOP lowering agents with an improved therapeutic profile over PGE, and methods of their use. It has now unexpectedly been discovered that the presently claimed prostanoids meet this objective. Although certain analogs of prostaglandin E have been disclosed as ocular hypotensives in U.S. Pat. Nos. 5, 057, 621; 5, 698, 598; 5.462, 968; and 4, 822, 891, and by Woodward el al., J. Lipid Mediators, 6:545 (1993) , the presently claimed compounds of this invention are neither disclosed, claimed, nor Suggested in that art. Furthermore, certain compounds of the claimed invention in combination with prostaglandin FP receptor agonists (EP 603800 A1) or with clonidine derivatives (U.S. Pat. No. 5,811,443) have been claimed for treating glaucoma.
SUMMARY OF THE INVENTION
The present invention is directed to novel compositions, and methods of use in treating ocular disorders in mammals, and especially in humans. More specifically, and in preferred embodiments, the present invention encompasses composi tions containing certain prostaglandin E receptor agonists and methods for treating glaucoma and ocular hypertension.
DETAILED DESCRIPTION OF THE INVENTION
It has unexpectedly been found that the prostaglandin E agonists of the present invention exhibit an improved thera 3 peutic profile in the treatment of glaucoma and ocular hypertension when compared to natural prostaglandins and many of their known analogs. The prostaglandin Eagonists of the present invention may also be used to treat other ocular disorders, Such as optic nerve disorder, by retarding Visual field loSS and/or improving Visual acuity in the manner described in U.S. Pat. No. 5,773,471, the disclosure of which is incorporated herein by this reference. AS used herein, the terms "treat," "treating," and "treatment" include both active treatment of the targeted disorder or Symptoms thereof, as well as prophylactic treatment of those disorders or Symptoms in Susceptible or at risk patients. It is further intended and should be understood that treatment of disor derS Stated in the conjunctive, Such as "glaucoma and ocular hypertension, includes the disjunctive as well. The phrase should therefore be read to mean "glaucoma and/or ocular hypertension."
It is further contemplated that the compounds of the present inventions can be used with other medicaments known to be useful in the treatment of glaucoma or ocular hypertension, either Separately or in combination. AS used herein, the terms "pharmaceutically acceptable ester/pharmaceutically acceptable cationic Salt' means any ester/cationic Salt that would be Suitable for therapeutic administration to a patient by any conventional means Without Significant deleterious health consequences, and "ophthalmically acceptable ester/"ophthalmically accept able cationic Salt' means any pharmaceutically acceptable ester/cationic salt that would be suitable for ophthalmic application, i.e. non-toxic and non-irritating. The term "acyl" represents a group that is linked by a carbon atom that has a double bond to an oxygen atom and a single bond to another carbon atom.
The term "alkyl" includes straight or branched chain aliphatic hydrocarbon groups that are Saturated and have 1 to 15 carbon atoms. The alkyl groups may be Substituted with other groups, Such as halogen, hydroxyl or alkoxy. Preferred Straight or branched alkyl groups include methyl, ethyl, propyl, isopropyl, butyl and t-butyl.
The term "cycloalkyl" includes straight or branched chain, Saturated or unsaturated aliphatic hydrocarbon groups which connect to form one or more rings, which can be fused or isolated. The rings may be Substituted with other groups, Such as halogen, hydroxyl. alkoxy, or lower alkyl. Preferred cycloalkyl groups include cyclopropyl, cyclobutyl, cyclo pentyl and cyclohexyl.
The term "alkenyl' includes straight or branched chain hydrocarbon groups having 1 to 15 carbon atoms with at least one carbon-carbon double bond. The chain hydrogens may be Substituted with other groups, Such as halogen. Preferred Straight or branched alkeny groups include, allyl, 1-butenyl, 1-methyl-2-propenyl and 4-pentenyl. The term "cycloalkenyl' includes straight or branched chain, Saturated or unsaturated aliphatic hydrocarbon groups which connect to form one or more non-aromatic rings containing a carbon-carbon double bond, which can be fused or isolated. The rings may be Substituted with other groups, Such as halogen, hydroxyl, alkoxy, or lower alkyl. Preferred cycloalkenyl groups include cyclopentenyl and cyclohex enyl.
The term "alkoxy' represents an alkyl group attached through an OXygen linkage.
The term "lower alkyl represents alkyl groups containing one to six carbons (C-C).
The term "halogen' represents fluoro, chloro, bromo, or iodo.
The term "aryl" refers to carbon-based rings which are aromatic. The rings may be isolated, Such as phenyl, or fused, Such as naphthyl. The ring hydrogens may be Sub Stituted with other groups, Such as lower alkyl, or halogen.
The term "heteroaryl" refers to aromatic hydrocarbon rings which contain at least one heteroatom Such as O, S, or N in the ring. Heteroaryl rings may be isolated, with 5 to 6 ring atoms, or fused, with 8 to 10 atoms. The heteroaryl
ring(s) hydrogens or heteroatoms with open Valency may be
Substituted with other groups, Such as lower alkyl or halo gen. Examples of heteroaryl groups include imidazole, pyridine, indole, quinoline, furan, thiophene, pyrrole, tetrahydroquinoline, dihydrobenzofuran, and dihydroben Biochemical Pharmacology, 53:1249 Pharmacology, 53: -1255 Pharmacology, 53: (1997 ). These ocular tissues are known to be heavily involved in the production of the aqueous humor. EP receptorS also modu late Salt and water transport in the kidney (Sakairi et al.
Luminal prostaglandin E receptorS regulate Salt and water transport in rabbit cortical collecting duct. American J.
Physiology, 269 (2 Pt. 2): F257-F265 (1995); Breyer et al. Ophthalmology, 41 (Supplement 2) S1-S14 (1997)), selec tive agonists for their respective receptors do not signifi cantly activate the EP receptor as shown in Table 1 below.
We have now discovered that EP receptor mRNA is present in human trabecular meshwork cells (see example 2 below). Based on this unexpected discovery we theorize that Table 1 below, certain compounds were Significantly more potent agonists at the EP receptor than at the EP receptor, making them relatively "EP-selective". On the other hand, butaprost and ZK118182 were more EP-selective compounds, whilst cloprostenol and fluprostenol (EP-/FP selective) were inactive at the EP and EP receptors. Total ribonucleic acid (RNA) was isolated from cells of interest using the well known guanidine thiocyanate-phenol chloroform extraction procedure (Chomczynski and Sacchi, Analytical Biochemistry, 162: 156-163 (1987) ). The iso lated RNA was reverse transcribed into complementary DNA (cDNA) using the well known protocol outlined in the GeneAmp RNA PCR kit (Perkin Elmer/Cetus, Norwalk, Conn.). The technique of reverse transcriptase polymerase chain reaction (RT-PCR) using oligonucleotide primers for the different human prostaglandin receptorS was employed to detect the messenger RNAs (mRNAs) for various pros taglandin receptors in human trabecular meshwork, choroi dal and iridial melanocytes as previously described (Senchyna and Crankshaw, Use of reverse transcription polymerase chain reaction to identify proStanoid receptor mRNA in human myometrium. British J. Pharmacology, 116: 280 (1995)). As can be seen in Table 2 Eye Research, 18, 91-119 (1998) The prostaglandin Eagonists of the present invention may be contained in various types of pharmaceutical compositions, in accordance with formulation techniques known to those skilled in the art. In general, these com pounds will be formulated in Solutions for topical oph thalmic administration. Solutions, Suspensions and other dosage forms are particularly preferred for the treatment of glaucoma and/or ocular hypertension.
The ophthalmic compositions of the present invention will include one or more compounds of the present invention in a pharmaceutically acceptable vehicle. Various types of vehicles may be used. Aqueous Solutions are generally preferred, based on ease of formulation, biological compatibility, as well as a patient's ability to easily admin ister Such compositions by means of instilling one to two drops of the solutions in the affected eyes. However, the compounds of the present invention may also be readily incorporated into other types of compositions, Such as Suspensions, Viscous or Semi-Viscous gels, or other types of Solid or Semi-Solid compositions. Suspensions may be pre ferred for those compounds of the present invention which are leSS Soluble in water. The ophthalmic compositions of the present invention may also include various other ingredients, Such as buffers, preservatives, co-Solvents and Viscosity building agents.
An appropriate buffer System (e.g., Sodium phosphate, Sodium acetate or Sodium borate) may be added to prevent pH drift under Storage conditions. Antioxidants may be added to compositions of the present invention to protect the EP agonists from oxidation during Storage. Examples of Such antioxidants include Vitamin E and analogs thereof, ascorbic acid and butylated hydroxy toluene (BHT).
Ophthalmic products are typically packaged in multidose form. Preservatives are thus required to prevent microbial contamination during use. Suitable preservatives include: benzalkonium chloride, thimerosal, chlorobutanol, methyl paraben, propyl paraben, phenylethyl alcohol, edetate disodium, Sorbic acid, polyguaternium-1, or other agents known to those skilled in the art. Such preservatives are typically employed at a level of from 0.001 to 1.0% weight/ volume ("% w/v).
In general, the doses used for the above described pur poses will vary, but will be in an effective amount to decrease intraocular pressure and thus treat or improve glaucomatous conditions. AS used herein, the term "phar maceutically effective amount" refers to an amount which lowers intraocular pressure and/or improves the glaucoma tous condition in a mammalian, preferably human, patient. When the compositions are dosed topically, they will gen
